146 related articles for article (PubMed ID: 34280441)
1. A prospective cohort study to assess the acceptability of Sayana Press among 18-49-year-old women in Nepal.
Sherpa LY; Tinkari BS; Gentle P; Sah RK; Shrestha A; Sahani SK; Aryal K; Ghimire J; Karki DK
Contraception; 2021 Dec; 104(6):623-627. PubMed ID: 34280441
[TBL] [Abstract][Full Text] [Related]
2. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.
MacLachlan E; Atuyambe LM; Millogo T; Guiella G; Yaro S; Kasasa S; Bukenya J; Nyabigambo A; Mubiru F; Tumusiime J; Onadja Y; Zan LM; Goeum/Sanon C; Kouanda S; Namagembe A
Contraception; 2018 Nov; 98(5):423-429. PubMed ID: 30125558
[TBL] [Abstract][Full Text] [Related]
3. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
[TBL] [Abstract][Full Text] [Related]
4. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda.
Cover J; Namagembe A; Tumusiime J; Nsangi D; Lim J; Nakiganda-Busiku D
Contraception; 2018 Nov; 98(5):383-388. PubMed ID: 29654751
[TBL] [Abstract][Full Text] [Related]
5. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
[TBL] [Abstract][Full Text] [Related]
6. Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal.
Burke HM; Mueller MP; Packer C; Perry B; Bufumbo L; Mbengue D; Daff BM; Mbonye A
Contraception; 2014 May; 89(5):368-73. PubMed ID: 24576792
[TBL] [Abstract][Full Text] [Related]
7. Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.
Cover J; Ba M; Drake JK; NDiaye MD
Contraception; 2019 Feb; 99(2):137-141. PubMed ID: 30439358
[TBL] [Abstract][Full Text] [Related]
8. Acceptability of the contraceptive Sayana® Press when injected every four months: Results from a twelve-month trial in Brazil, Chile and the Dominican Republic.
Burke HM; Packer C; Fuchs R; Brache V; Bahamondes L; Salinas A; Veiga N; Miller A; Deese J
Contraception; 2022 Sep; 113():95-100. PubMed ID: 35483431
[TBL] [Abstract][Full Text] [Related]
9. Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.
Stout A; Wood S; Barigye G; Kaboré A; Siddo D; Ndione I
Glob Health Sci Pract; 2018 Mar; 6(1):55-72. PubMed ID: 29602866
[TBL] [Abstract][Full Text] [Related]
10. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
[TBL] [Abstract][Full Text] [Related]
11. Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings.
Keith B; Wood S; Tifft S; Hutchings J
Contraception; 2014 May; 89(5):344-51. PubMed ID: 24813924
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study.
Cover J; Ba M; Lim J; Drake JK; Daff BM
Contraception; 2017 Sep; 96(3):203-210. PubMed ID: 28673645
[TBL] [Abstract][Full Text] [Related]
13. Perceptions of home and self-injection of Sayana® Press in Ethiopia: a qualitative study.
Keith B; Wood S; Chapman C; Alemu E
Contraception; 2014 May; 89(5):379-84. PubMed ID: 24529492
[TBL] [Abstract][Full Text] [Related]
14. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
15. Operational assessments of Sayana® Press provision in Senegal and Uganda.
Cover J; Blanton E; Ndiaye D; Walugembe F; Lamontagne DS
Contraception; 2014 May; 89(5):374-8. PubMed ID: 24565737
[TBL] [Abstract][Full Text] [Related]
16. Pilot Research as Advocacy: The Case of Sayana Press in Kinshasa, Democratic Republic of the Congo.
Binanga A; Bertrand JT
Glob Health Sci Pract; 2016 Dec; 4(4):542-551. PubMed ID: 27979874
[TBL] [Abstract][Full Text] [Related]
17. Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from Uganda.
Di Giorgio L; Mvundura M; Tumusiime J; Morozoff C; Cover J; Drake JK
Contraception; 2018 Nov; 98(5):396-404. PubMed ID: 30098940
[TBL] [Abstract][Full Text] [Related]
18. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
[TBL] [Abstract][Full Text] [Related]
19. Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda.
Odwe G; Gray K; Kyarimpa A; Obare F; Nagendi G
Glob Health Sci Pract; 2018 Dec; 6(4):711-722. PubMed ID: 30429201
[TBL] [Abstract][Full Text] [Related]
20. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood.
Kohn JE; Simons HR; Della Badia L; Draper E; Morfesis J; Talmont E; Beasley A; McDonald M; Westhoff CL
Contraception; 2018 Mar; 97(3):198-204. PubMed ID: 29246818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
